Clinical Trial Update: Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update on MAZ-101 for persistent allergic rhinitis, focusing on efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• MAZ-101

Snippet

Sponsor: EMS | Conditions: Allergic Rhinitis | Phase 3 | Status: UNKNOWN